Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 32,200 shares, a drop of 18.1% from the March 15th total of 39,300 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average trading volume of 11,900 shares, the days-to-cover ratio is currently 2.7 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $9.00 price target on shares of Prenetics Global in a report on Thursday, January 16th.

Prenetics Global Stock Performance

Prenetics Global stock traded up $0.29 during mid-day trading on Monday, hitting $4.30. The company’s stock had a trading volume of 19,290 shares, compared to its average volume of 30,532. The company has a 50 day moving average of $4.42 and a 200-day moving average of $4.86. Prenetics Global has a one year low of $2.95 and a one year high of $7.84. The stock has a market cap of $52.48 million, a PE ratio of -1.08 and a beta of -0.20.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.